Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

12.83 -0.38 (-2.88%)
Delayed Quote Updated: 2:19 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform ↗
Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to... 
Via MarketBeat
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Arcturus (ARCT) Q2 2026 Earnings Call Transcript ↗
Regaining vaccine rights and advancing rare disease programs toward key 2026 milestones. 
Via The Motley Fool
Topics Earnings
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances ↗
Via Chartmill
Arcturus Therapeutics (NASDAQ:ARCT) Stock Falls After Q4 2025 Revenue Miss ↗
Via Chartmill
News headline image
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline ↗
Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is... 
Via MarketBeat
News headline image
Arcturus Therapeutics Q2 Earnings Call Highlights ↗
Arcturus Therapeutics (NASDAQ:ARCT) reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase... 
Via MarketBeat
Topics Earnings
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies ↗
Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the... 
Via MarketBeat
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Preview: Arcturus Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Arcturus (ARCT) Q1 2026 Earnings Call Transcript ↗
Arcturus (ARCT) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The widely followed investor has been buying stocks trading well below their all-time highs. 
Via The Motley Fool
News headline image
These Are the Only 3 Stocks That Cathie Wood Bought Last Week ↗
The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Arcturus (ARCT) Q4 2025 Earnings Call Transcript ↗
Arcturus (ARCT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Lawsuit
News headline image
Arcturus Therapeutics (NASDAQ:ARCT) Reports Mixed Q3 2025 Results, Extends Cash Runway to 2028 ↗
Arcturus Q3 2025 results show a revenue miss but a smaller-than-expected loss. The company advances its CF and OTC programs, with cash extending into 2028. 
Via Chartmill
News headline image
This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Cathie Wood Goes Shopping: 3 Stocks She Just Bought ↗
The growth-focused money manager only bought three stocks on Wednesday. Let's check out that shopping list. 
Via The Motley Fool
Topics ETFs
News headline image
Where Arcturus Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture ↗
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement. 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off? ↗
The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing. 
Via Stocktwits
News headline image
Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug ↗
The company is working on a treatment for cystic fibrosis using messenger RNA, or mRNA, technology. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.